Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has emerged as a powerful immunotherapy for solid tumors, yet its broader application is constrained by reliance on high-dose interleukin-2 (IL-2), a cytokine that activates T cells but also drives T-cell exhaustion and causes severe toxicity.